Complement C1 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Complement C1 Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement C1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Complement C1 Inhibitors: Overview
Complement C1 is the defining component of the classical pathway. Within the C1qC1r2C1s2 complex, C1q functions as a molecular scaffold for C1r2C1s2 and C1q binding to its ligands activates these two serine proteases. The classic C1q ligands are antigen-bound antibodies and activated C1s cleaves C4 and C2 to initiate the complement cascade.
Function - Activation of the C1 complex initiates the classical complement pathway. This occurs when C1q binds to antigen-antibody complexes. The antibodies IgM or certain subclasses of IgG complexed with antigens are able to initiate the complement system: a single pentameric IgM can initiate the pathway, while several monomeric IgG molecules are needed. C1q can also be activated in other ways, for example by binding to pentraxins such as C-reactive protein or directly to the surface of pathogens.
Complement C1 Inhibitors - C1 inhibitor is a protease inhibitor that targets C1r and C1s enzymes of the classical pathway of complement, Hageman factor (factor XII) of the coagulation pathway, and the kallikrein system.
Complement C1 Inhibitors Emerging Drugs Chapters
This segment of the Complement C1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complement C1 Inhibitors Emerging Drugs
Further product details are provided in the report……..
Complement C1 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Complement C1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Complement C1 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement C1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement C1 Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Complement C1 Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement C1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Complement C1 Inhibitors: Overview
Complement C1 is the defining component of the classical pathway. Within the C1qC1r2C1s2 complex, C1q functions as a molecular scaffold for C1r2C1s2 and C1q binding to its ligands activates these two serine proteases. The classic C1q ligands are antigen-bound antibodies and activated C1s cleaves C4 and C2 to initiate the complement cascade.
Function - Activation of the C1 complex initiates the classical complement pathway. This occurs when C1q binds to antigen-antibody complexes. The antibodies IgM or certain subclasses of IgG complexed with antigens are able to initiate the complement system: a single pentameric IgM can initiate the pathway, while several monomeric IgG molecules are needed. C1q can also be activated in other ways, for example by binding to pentraxins such as C-reactive protein or directly to the surface of pathogens.
Complement C1 Inhibitors - C1 inhibitor is a protease inhibitor that targets C1r and C1s enzymes of the classical pathway of complement, Hageman factor (factor XII) of the coagulation pathway, and the kallikrein system.
Complement C1 Inhibitors Emerging Drugs Chapters
This segment of the Complement C1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complement C1 Inhibitors Emerging Drugs
- Sutimlimab : Bioverativ
- ANX007 : Annexon
Further product details are provided in the report……..
Complement C1 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Complement C1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Complement C1 Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Complement C1 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement C1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement C1 Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Complement C1 Inhibitors R&D. The therapies under development are focused on novel approaches for Complement C1 Inhibitors.
- Complement C1 Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Complement C1 Inhibitors drugs?
- How many Complement C1 Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Complement C1 Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Complement C1 Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complement C1 Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bioverativ
- Annexon
- Pharming Group NV
- CSL Behring
- Takeda
- Octapharma
- BioGenius
- True North Therapeutics
- Sutimlimab
- ANX 007
- Conestat alfa
- Complement C1 inhibitor protein
- TAK-616
- OCTA-C1-INH
- Bicizar
- ANX 005
- BIVV 020
Introduction
Executive Summary
Complement C1 Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Complement C1 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Complement C1 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Complement C1 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Sutimlimab: Bioverativ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ANX007: Annexon
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Complement C1 Inhibitors Key Companies
Complement C1 Inhibitors Key Products
Complement C1 Inhibitors- Unmet Needs
Complement C1 Inhibitors- Market Drivers and Barriers
Complement C1 Inhibitors- Future Perspectives and Conclusion
Complement C1 Inhibitors Analyst Views
Complement C1 Inhibitors Key Companies
Appendix
Executive Summary
Complement C1 Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Complement C1 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Complement C1 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Complement C1 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Sutimlimab: Bioverativ
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ANX007: Annexon
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Complement C1 Inhibitors Key Companies
Complement C1 Inhibitors Key Products
Complement C1 Inhibitors- Unmet Needs
Complement C1 Inhibitors- Market Drivers and Barriers
Complement C1 Inhibitors- Future Perspectives and Conclusion
Complement C1 Inhibitors Analyst Views
Complement C1 Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Complement C1 Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Complement C1 Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Complement C1 Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Complement C1 Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
